 In March 2020, the Company announced it had received 1.13 million for its 2018 CIR for an aggregate total of 1.77 million in non-dilutive funding received in 2020. In addition, the Company anticipates it will receive the 2019 CIR payment by the end of 2020. The CIR has been used to fund AzurRxs ongoing MS1819 clinical trials, including its Phase 2 Combination therapy study in Cystic Fibrosis. 